AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

CLASS ACTION UPDATE for CRCM, CRBP, ARA and MWA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

May 9, 2019

NEW YORK, May 09, 2019 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.

Care.com, Inc. (NYSE: CRCM) Class Period: March 27, 2015 - April 1, 2019 Lead Plaintiff Deadline: June 3, 2019 Join the action: https://www.zlk.com/pslra-1/care-com-inc-loss-form?wire=3

The complaint alleges that Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts, with respect to the manner in which the Company vets the caregivers and daycare providers listed on its website.

To learn more about the Care.com, Inc. class action contact jlevi@levikorsinsky.com.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQGM: CRBP) Class Period: November 14, 2016 - February 28, 2019 Lead Plaintiff Deadline: May 13, 2019 Join the action: https://www.zlk.com/pslra-1/corbus-pharmaceutical-holdings-inc-loss-form?wire=3

The lawsuit alleges: Corbus Pharmaceuticals Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Corbus improperly changed the primary efficacy endpoint for the clinical study of its drug candidate, Lenabasum, after the results were unblinded to Corbus; (2) Corbus reported a one-sided p value, not the traditional two-sided p value normally reported in clinical trials, in an effort to conceal the fact that the study results did not have statistical significance; and (3) as a result, Corbus’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To learn more about the Corbus Pharmaceuticals Holdings, Inc. class action contact jlevi@levikorsinsky.com.

American Renal Associates Holdings, Inc. (NYSE: ARA) Class Period: August 10, 2016 - March 27, 2019 Lead Plaintiff Deadline: May 28, 2019 Join the action: https://www.zlk.com/pslra-1/american-renal-associates-holdings-inc-loss-form?wire=3

The lawsuit alleges that, during the class period, American Renal Associates Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) issues with American Renal’s accounting process for revenue recognition, collections, and related matters would give rise to a U.S. Securities and Exchange Commission (“SEC”) investigation into the same, and increased regulatory scrutiny by the SEC; (2) financial statements for the fiscal years 2014, 2015, 2016 and 2017 contained in its Annual Reports for the years ended December 31, 2016 and 2017, and its condensed consolidated financial statements in quarterly reports from 2016 through 2018, were false and could not be relied upon; (3) American Renal had material weaknesses in its internal control over financial reporting; and (4) as a result, defendants’ public statements were materially false and misleading at all relevant times.

To learn more about the American Renal Associates Holdings, Inc. class action contact jlevi@levikorsinsky.com.

Mueller Water Products, Inc. (NYSE: MWA) Class Period: May 9, 2016 - August 6, 2018 Lead Plaintiff Deadline: June 10, 2019 Join the action: https://www.zlk.com/pslra-1/mueller-water-products-inc-loss-form?wire=3

The lawsuit alleges: Mueller Water Products, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company lacked adequate testing for product quality; (2) certain products with radio components were susceptible to fail prematurely; (3) as a result, the Company was reasonably likely to incur increased expenses, including warranty costs; (4) these costs would materially impact the Company’s financial statements; (5) the Company lacked adequate internal controls over warranty costs and estimates; and (6) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more about the Mueller Water Products, Inc. class action contact jlevi@levikorsinsky.com.

You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.55 Broadway, 10th FloorNew York, NY 10006 jlevi@levikorsinsky.com Tel: (212) 363-7500Toll Free: (877) 363-5972Fax: (212) 363-7171 www.zlk.com